Literature DB >> 25280999

Establishment of a mouse melanoma model system for the efficient infection and replication of human adenovirus type 5-based oncolytic virus.

Sujin Kang1, Joo-Hang Kim2, So Young Kim1, Dongxu Kang3, Suyeon Je1, Jae J Song4.   

Abstract

Due to poor adenoviral infectivity and replication in mouse tumor cell types compared with human tumor cell types, use of human-type adenoviral vectors in mouse animal model systems was limited. Here, we demonstrate enhanced infectivity and productive replication of adenovirus in mouse melanoma cells following introduction of both the Coxsackievirus and adenovirus receptor (CAR) and E1B-55K genes. Introduction of CAR into B16BL6 or B16F10 cells increased the infectivity of GFP-expressing adenovirus; however, viral replication was unaffected. We demonstrated a dramatic increase of adenoviral replication (up to 100-fold) in mouse cells via E1B-55K expression and subsequent viral spreading in mouse tissue. These results reveal for the first time that human adenovirus type 5 (Ad5)-based oncolytic virus can be applied to immunocompetent mouse with the introduction of CAR and E1B-55K to syngenic mouse cell line.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CAR; E1B-55K; Mouse melanoma; Oncolytic adenovirus

Mesh:

Substances:

Year:  2014        PMID: 25280999     DOI: 10.1016/j.bbrc.2014.09.107

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  Temozolomide renders murine cancer cells susceptible to oncolytic adenovirus replication and oncolysis.

Authors:  Rodolfo Garza-Morales; Kavitha Yaddanapudi; Rigoberto Perez-Hernandez; Eric Riedinger; Kelly M McMasters; Haval Shirwan; Esma Yolcu; Roberto Montes de Oca-Luna; Jorge G Gomez-Gutierrez
Journal:  Cancer Biol Ther       Date:  2018-01-22       Impact factor: 4.742

2.  Adenovirus Lacking E1b Efficiently Induces Cytopathic Effect in HPV-16-Positive Murine Cancer Cells via Virus Replication and Apoptosis.

Authors:  Elvis Martinez-Jaramillo; Rodolfo Garza-Morales; Stephen L Wechman; Roberto Montes de Oca-Luna; Odila Saucedo-Cardenas; Haval Shirwan; Esma Yolcu; Kelly M McMasters; Jorge G Gomez-Gutierrez
Journal:  Cancer Invest       Date:  2018-02-01       Impact factor: 2.176

3.  Cytotoxicity of replication-competent adenoviruses powered by an exogenous regulatory region is not linearly correlated with the viral infectivity/gene expression or with the E1A-activating ability but is associated with the p53 genotypes.

Authors:  Suguru Yamauchi; Boya Zhong; Kiyoko Kawamura; Shan Yang; Shuji Kubo; Masato Shingyoji; Ikuo Sekine; Yuji Tada; Koichiro Tatsumi; Hideaki Shimada; Kenzo Hiroshima; Masatoshi Tagawa
Journal:  BMC Cancer       Date:  2017-09-05       Impact factor: 4.430

4.  Prime-boost immunization by both DNA vaccine and oncolytic adenovirus expressing GM-CSF and shRNA of TGF-β2 induces anti-tumor immune activation.

Authors:  So Young Kim; Dongxu Kang; Hye Jin Choi; Yeonsoo Joo; Joo-Hang Kim; Jae J Song
Journal:  Oncotarget       Date:  2017-02-28

5.  Cell-Surface Integrins and CAR Are Both Essential for Adenovirus Type 5 Transduction of Canine Cells of Lymphocytic Origin.

Authors:  Payal Agarwal; Elizabeth A Gammon; Abdul Mohin Sajib; Maninder Sandey; Bruce F Smith
Journal:  PLoS One       Date:  2017-01-09       Impact factor: 3.240

6.  Enhanced tumor targeting and timely viral release of mesenchymal stem cells/oncolytic virus complex due to GRP78 and inducible E1B55K expressions greatly increase the antitumor effect of systemic treatment.

Authors:  Soojin Choi; Jeong A Hong; Hye Jin Choi; Jae J Song
Journal:  Mol Ther Oncolytics       Date:  2022-09-17       Impact factor: 6.311

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.